|
業務類別
|
Biotechnology |
|
業務概覽
|
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally. |
| 公司地址
| 12390 El Camino Real, San Diego, CA, USA, 92130 |
| 電話號碼
| +1 858 794-8889 |
| 傳真號碼
| +1 858 704-8311 |
| 公司網頁
| https://www.halozyme.com |
| 員工數量
| 423 |
| Mr. David A. Ramsay |
Interim Chief Financial Officer |
-- |
30/04/2026 |
| Ms. Cortney Caudill |
Senior Vice President and Chief Operating Officer |
美元 561.00K |
17/02/2026 |
| Dr. Helen I. Torley, M.R.C.P.,MB.Ch.B. |
Director, President and Chief Executive Officer |
美元 1.00M |
23/03/2026 |
| Mr. Mark Snyder |
Senior Vice President, General Counsel, Chief Compliance Officer, Chief Legal Officer and Secretary |
美元 619.00K |
23/03/2026 |
|
|
| Mr. James Lang |
Independent Director |
23/03/2026 |
| Mr. Jeffrey W. Henderson |
Chairman of the Board |
23/03/2026 |
| Dr. Helen I. Torley, M.R.C.P.,MB.Ch.B. |
Director, President and Chief Executive Officer |
23/03/2026 |
| Mr. Matthew L. Posard |
Independent Director |
23/03/2026 |
| Ms. Bernadette M. Connaughton |
Independent Director |
23/03/2026 |
| Ms. Barbara G. Duncan |
Independent Director |
23/03/2026 |
| Ms. Moni Miyashita |
Independent Director |
23/03/2026 |
| Dr. Mahesh Krishnan, M.B.A. |
Independent Director |
23/03/2026 |
|
|
|
|
